NCT05800340View on ClinicalTrials.gov

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 MutationErb-B2 Receptor Tyrosine Kinase Exon 20 MutationMET AmplificationMET Exon 14 Skipping Mutation
Interventions
BIOLOGICAL

Toripalimab

240mg Q3W

DRUG

Nab paclitaxel

135 mg/m2, d1, 8 Q3W

DRUG

Pemetrexed

500mg/m2, d1 Q3W

DRUG

Carboplatin

AUC 5, d1 Q3W

Trial Locations (1)

510080

RECRUITING

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guanzhou

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Guangdong Provincial People's Hospital

OTHER